18 February 2016
LivaNova PLC (the “Company” or “LivaNova”) announces on 16 February 2016, Daniel J. Moore, who is a PDMR and Director of LivaNova, disposed of 1,000 ordinary shares of £1.00 each in the capital of the Company (the “Ordinary Shares”) for an average price of US $56.8760 per Ordinary Share. As a result of this transaction, Daniel J. Moore currently holds 66,437 Ordinary Shares, representing 0.14 per cent of the Company’s issued share capital (which excludes the 2,233 Ordinary Shares that he is entitled to in relation to his Restricted Stock Units (subject to vesting periods and the terms of the LivaNova 2015 Incentive Award Plan)).
This announcement is made pursuant to the Disclosure and Transparency Rule 3.1.4R.
LivaNova PLC, headquartered in London, UK, is a global medical technology company formed by the merger of Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and Cyberonics Inc., a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals, and healthcare systems. The company employs approximately 4,500 employees worldwide. With a presence in more than 100 countries, LivaNova operates as three business units: Cardiac Rhythm Management, Cardiac Surgery, and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.), respectively.
LivaNova is listed on NASDAQ and listed on the Official List of the UK’s Financial Conduct Authority and traded on London Stock Exchange (LSE) under the ticker symbol “LIVN”.
For more information, please visit www.livanova.com, or contact:
Chief Financial Officer
Investor Relations and Media:
- End -